By Rosie Wilson

ATX-101, a non-surgical solution to double chins developed by Kythera Biopharmaceuticals Inc., has been unanimously backed by an FDA advisory panel, according to the company.

Kythera made a new drug application for ATX-101 in July 2014, and if the drug is approved by the FDA, the company plans to launch the treatment in the second half of this year. Advisory panel recommendations are not binding, but are considered by the FDA and can often influence the final decision.

ATX-101 has been the subject of 19 separate clinical trials, which have totalled in around 2,600 patients being treated. The treatment would represent a new product category.

For more information, see